Analysis – Page 351 – Goldea Capital

Flagship Communities Real Estate Investment Trust Announces May 2026 Cash Distribution

Written by Customer Service on May 15, 2026. Posted in Dividend Reports And Estimates.

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, May 15, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX:MHC.U) (TSX:MHC.UN) today announced a cash distribution of US$0.0545 per REIT unit for the month of May 2026, representing US$0.654 per REIT unit on an annualized basis. Payments will be made on or about June 15, 2026, to unitholders of record as of the close of business on May 29, 2026. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstance. About Flagship Communities Real Estate Investment...

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q1 2026 Results and Files Form 10-Q; Total Assets Reach Over $26.0 Million, Up 102% from Year-End 2025 and 193% Year-over-Year

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

NEWPORT BEACH, Calif., May 15, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the three months ended March 31, 2026, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the Company’s filings. Q1 2026 was a quarter of meaningful balance sheet growth, driven by the Company’s financing and M&A activities, including the closing of the SVM Machining Inc. (“SVM”) acquisition. SVM is a Northern California-based precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. Balance Sheet HighlightsTotal assets increased...

Bera hf.: Verkaskipting stjórnar í kjölfar aðalfundar

Written by Customer Service on May 15, 2026. Posted in Public Companies.

Að loknum aðalfundi Beru hf., sem haldinn var þann 13. maí 2026, hélt nýkjörin stjórn sinn fyrsta stjórnarfund og skipti með sér verkum. Andri Þór Guðmundsson var kjörinn formaður stjórnar og Rannveig Eir Einarsdóttir varaformaður.

Form 8.3 – TATE & LYLE PLC

Written by Customer Service on May 15, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Jupiter Fund Management Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of Offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree TATE & LYLE PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held: For an opening position disclosure,...

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2026 and provided an update on the continued commercialization of neffy®...

H World Group Limited Reports First Quarter of 2026 Unaudited Financial Results

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

A total of 13,215 hotels or 1,303,563 hotel rooms in operation as of March 31, 2026. Hotel turnover1 increased 17.4% year-over-year to RMB26.4 billion in the first quarter of 2026. Excluding H World International (“HWI”)2, hotel turnover from the H World China (“HWC”)3 segment increased 18.0% year-over-year in the first quarter of 2026. Hotel turnover from the HWI segment increased 9.6% year-over-year in the first quarter of 2026. Revenue in the first quarter of 2026 increased 11.1% year-over-year to RMB6.0 billion (US$870 million)4. Manachised and franchised (“M&F”) revenue increased 20.3% year-over-year to RMB3.0 billion (US$436 million) over the same period. Revenue from the HWC segment in the first quarter of 2026 was RMB5.0 billion, which increased 12.4% year-over-year; and HWI segment revenue in the first quarter of 2026 was...

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 14 05 2026] – (CGAML)

Written by Customer Service on May 15, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 14 05 2026] – (CGWL)

Written by Customer Service on May 15, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [ANIMALCARE GROUP PLC – 14 05 2026] – (CGWL)

Written by Customer Service on May 15, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Initiation of buy-back programme

Written by Customer Service on May 15, 2026. Posted in Public Companies.

ANNOUNCEMENT NO. 309 15 May 2026 Initiation of buy-back programme The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 9 October 2025. The authorisation is valid until the next Annual General Meeting, which will be held on 8 October 2026 and covers up to 10% of the share capital. At the start of the share buy-back programme, ChemoMetec A/S does not hold any own shares. The purpose of the share buy-back programme is to adjust the company’s capital structure. The share buy-back programme runs from 18 May 2026 up to and including 8 October 2026. The share buy-back programme is carried out without the application of the Safe Harbour rules in Article 5 of the Market Abuse Regulation. The buy-back is carried out at market price and in accordance...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals